Posted by Michael Wonder on 11 Jan 2026
Camurus announces FDA acceptance of NDA resubmission for Oclaiz for the treatment of acromegaly
9 January 2026 - Camurus today announced that the US FDA has accepted for review the company's resubmission of the new drug application for Oclaiz (CAM2029), octreotide extended-release injection, for the treatment of patients with acromegaly.
The FDA has assigned a PDUFA target action date of 10 June 2026.
